Sinovac Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities

December 10, 2009

Sinovac Biotech Ltd. (Beijing, China), a developer and provider of vaccines, has executed a joint venture agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).

Sinovac Biotech Ltd. (Beijing, China), a developer and provider of vaccines, has executed a joint venture agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The joint venture will research, develop, produce, and commercialize vaccines for human use. Sinovac will contribute its expertise and experience in developing and commercializing vaccines; the other party will bring its land use rights, manufacturing facilities, and established operating infrastructure.

Sinovac Dalian, headquartered in Dalian, Liaoning Province, will occupy a total area of approximately 1,000,000 square feet. The campus currently contains two vaccine production lines—one for the Vero cell cultured vaccines and one for live attenuated vaccines—and has capacity to house approximately six different production lines. In addition, the headquarters features quality assurance and quality control facilities, a research laboratory, an office building, and a warehouse.

Sinovac Dalian's development pipeline is expected to comprise vaccines for rabies, mumps, varicella, and rubella. The facility has a designed annual manufacturing capacity of 20 million doses of Vero cell cultured vaccines and 20 million doses of live attenuated vaccines.